Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -1.02 Million USD | 1.67% |
| 2021 | -1.03 Million USD | -9803.12% |
| 2020 | 10.7 Thousand USD | 112.88% |
| 2019 | -83.14 Thousand USD | -172.41% |
| 2018 | 114.81 Thousand USD | 251.22% |
| 2017 | 32.69 Thousand USD | -85.25% |
| 2016 | 221.58 Thousand USD | 90.45% |
| 2015 | 116.34 Thousand USD | -64.04% |
| 2014 | 323.52 Thousand USD | -6.61% |
| 2013 | 346.43 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | -115.68 Thousand USD | 54.7% |
| 2022 Q1 | -255.37 Thousand USD | 1.67% |
| 2022 Q4 | -255.37 Thousand USD | -116.61% |
| 2022 Q3 | -117.89 Thousand USD | -1.91% |
| 2022 FY | -1.02 Million USD | 1.67% |
| 2021 Q2 | -92.42 Thousand USD | 64.41% |
| 2021 FY | -1.03 Million USD | -9803.12% |
| 2021 Q4 | -259.7 Thousand USD | -180.97% |
| 2021 Q3 | -92.43 Thousand USD | -0.0% |
| 2021 Q1 | -259.7 Thousand USD | 81.54% |
| 2020 Q1 | -80.72 Thousand USD | 22.87% |
| 2020 Q2 | -93.22 Thousand USD | -15.49% |
| 2020 Q3 | -217.43 Thousand USD | -133.22% |
| 2020 Q4 | -1.4 Million USD | -547.0% |
| 2020 FY | 10.7 Thousand USD | 112.88% |
| 2019 Q1 | -99.31 Thousand USD | -358.38% |
| 2019 Q2 | 8691.00 USD | 108.75% |
| 2019 Q3 | -4778.00 USD | -154.98% |
| 2019 Q4 | -104.65 Thousand USD | -2090.35% |
| 2019 FY | -83.14 Thousand USD | -172.41% |
| 2018 FY | 114.81 Thousand USD | 251.22% |
| 2018 Q4 | 38.43 Thousand USD | 170.11% |
| 2018 Q1 | - USD | 100.0% |
| 2018 Q2 | -62.14 Thousand USD | 0.0% |
| 2018 Q3 | 14.23 Thousand USD | 122.9% |
| 2017 FY | 32.69 Thousand USD | -85.25% |
| 2017 Q4 | -32.69 Thousand USD | 47.4% |
| 2017 Q3 | -62.14 Thousand USD | -10.07% |
| 2017 Q2 | -56.45 Thousand USD | -311.61% |
| 2017 Q1 | 26.68 Thousand USD | -32.33% |
| 2016 FY | 221.58 Thousand USD | 90.45% |
| 2016 Q1 | 35.89 Thousand USD | -69.15% |
| 2016 Q2 | -34.62 Thousand USD | -196.45% |
| 2016 Q3 | -37.6 Thousand USD | -8.62% |
| 2016 Q4 | 39.42 Thousand USD | 204.84% |
| 2015 Q1 | -7531.00 USD | 96.55% |
| 2015 Q2 | -7432.00 USD | 1.31% |
| 2015 Q3 | 53.73 Thousand USD | 823.06% |
| 2015 FY | 116.34 Thousand USD | -64.04% |
| 2015 Q4 | 116.34 Thousand USD | 116.51% |
| 2014 FY | 323.52 Thousand USD | -6.61% |
| 2014 Q2 | 74.97 Thousand USD | 36.27% |
| 2014 Q4 | -218.18 Thousand USD | -314.55% |
| 2014 Q1 | 55.02 Thousand USD | 0.0% |
| 2014 Q3 | 101.69 Thousand USD | 35.64% |
| 2013 Q2 | -7691.00 USD | -222.2% |
| 2013 Q1 | -2387.00 USD | 0.0% |
| 2013 Q3 | -2274.00 USD | 70.43% |
| 2013 Q4 | - USD | 100.0% |
| 2013 FY | 346.43 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 100.0% |
| 2012 Q3 | -2166.00 USD | -21.89% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | -1777.00 USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 705.911% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -308.597% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -85.389% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -473.872% |
| Better Therapeutics, Inc. | -2.72 Million USD | 62.569% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 26.246% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 341.652% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 95.543% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 85.597% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -294.399% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -1838.39% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 63.465% |
| Molecular Templates, Inc. | 50.39 Million USD | 102.027% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -756.275% |
| NexImmune, Inc. | -1.02 Million USD | 0.339% |
| Orgenesis Inc. | -5.72 Million USD | 82.157% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 96.017% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -22101.543% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 103.476% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -109.188% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -340.299% |
| Trevena, Inc. | 1.45 Million USD | 170.206% |
| Vaxxinity, Inc. | -2.23 Million USD | 54.275% |
| Vaccinex, Inc. | -16 Million USD | 93.617% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -107.621% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 8898.389% |